Emerging concepts and recent advances in basal cell carcinoma

Emerging concepts and recent advances in basal cell... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/6-2085" }, "headline": "Emerging concepts and recent advances in basal cell carcinoma", "datePublished": "2017-12-04T11:30:19", "dateModified": "2017-12-04T11:30:19", "author": [ { "@type": "Person", "name": "Mariam Totonchy" }, { "@type": "Person", "name": "David Leffell" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/6-2085/v1", "name": "Emerging concepts and recent advances in basal cell carcinoma" } } ] } Home Browse Emerging concepts and recent advances in basal cell carcinoma ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Totonchy M and Leffell D. Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved] . F1000Research 2017, 6 (F1000 Faculty Rev):2085 ( https://doi.org/10.12688/f1000research.11314.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Review Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved] Mariam Totonchy https://orcid.org/0000-0001-7609-5235 1 , David Leffell 2 Mariam Totonchy https://orcid.org/0000-0001-7609-5235 1 , David Leffell 2 PUBLISHED 04 Dec 2017 Author details Author details 1 Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA 2 Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery, Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease. READ ALL READ LESS Keywords basal cell carcinoma,non-melanoma,squamous cell,vismodegib Corresponding Author(s) Mariam Totonchy ( [email protected] ) Close Corresponding author: Mariam Totonchy Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2017 Totonchy M and Leffell D. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Totonchy M and Leffell D. Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved] . F1000Research 2017, 6 (F1000 Faculty Rev):2085 ( https://doi.org/10.12688/f1000research.11314.1 ) First published: 04 Dec 2017, 6 (F1000 Faculty Rev):2085 ( https://doi.org/10.12688/f1000research.11314.1 ) Latest published: 04 Dec 2017, 6 (F1000 Faculty Rev):2085 ( https://doi.org/10.12688/f1000research.11314.1 ) Introduction Non-melanoma skin cancers (NMSCs), which include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common cancers in Caucasians. One in five Americans will develop skin cancer in their lifetime 1 . In 2012, 5.4 million NMSCs were diagnosed in the US alone 2 . BCC comprises approximately 80% of these NMSCs, and incidence rates are increasing worldwide 2 , 3 . Incidence rates of BCC in the US have risen by approximately 2% per year 3 , and there are significant increases among women and individuals younger than 40 years of age 3 – 6 . BCCs are treatable cancers and have low rates of metastasis and mortality 7 , 8 ; however, their high incidence rates and treatment costs contribute significantly to the rising economic burden of health care 9 . From 2007 to 2011, as compared with from 2002 to 2006, the aggregate cost of treating skin cancer in the US rose from $3.6 to $8.1 billion per year, and the average cost of treatment per patient has also increased significantly, from $1,000 in 2006 to $1,600 in 2011 9 – 11 . In addition to the rising cost of treatment, BCCs are associated with significant morbidity, making their management an important public health concern. Risk factors The increase in incidence rates of BCC may indicate changes in environmental or lifestyle and behavioral risk factors. Solar ultraviolet (UV) irradiation is a known risk factor for BCC 12 . Exposure to UV light, particularly UVB, induces mutations in tumor suppressor genes and plays a key role in the pathogenesis of BCC 13 – 15 . A history of blistering sunburn and younger age at first blistering sunburn have been associated with BCC, yet it is still unclear whether continuous or intermittent sun exposure poses a greater risk 16 – 18 . Exposure to UV radiation early in life or intermittent exposure throughout life may be more important than overall cumulative exposure 19 . In the past decade, indoor tanning has emerged as a significant risk factor for skin cancer, including early-onset BCC 20 – 24 . The melanocortin 1 receptor gene, MC1R , is associated with fair skin, red hair, and increased risk for melanoma and NMSC 25 – 30 . Both MC1R genotype and indoor tanning have been used to predict risk of early-onset BCC in statistical models 28 . Increasing age, male sex, and white race have also been correlated with higher rates of BCC 31 , 32 . Higher risk with age may be due in part to a reduced ability to repair DNA damage from UV radiation, leading to the accumulation of carcinogenic photoproducts 33 , 34 . Other important risk factors include a family history of skin cancer, fair complexion, light eye/hair color, and a low ability to tan 35 , 36 . Interestingly, a recent study also found that adult body mass index was inversely associated with early-onset BCC 37 . In addition to risk factors for developing BCC, there are certain features of BCCs that place them in a high-risk category. High-risk BCC features include tumors of longstanding duration, diameter of greater than 2 cm, aggressive histo-pathologic subtype, perivascular or perineural infiltration, location in the mid-face or ears, history of radiation exposure, and prior treatment failure 38 . Morpheaform, infiltrative, and micronodular histo-pathologic subtypes are considered aggressive. Chronically immunosuppressed patients are at high risk not only for NMSC but also for more aggressive phenotypes of these cutaneous carcinomas due to impaired immune surveillance of the skin 39 – 41 . Solid organ transplant recipients comprise an important subgroup of immunosuppressed patients for whom skin cancer is the most common post-transplant malignancy 42 – 46 . While the relative increased risk of developing SCC is higher compared with BCC in this group, the risk of BCC is still significantly increased at a factor of 7 to 20 as compared with the normal population 43 , 47 . The number of solid organ transplants in the US is increasing annually, making treatment of NMSC in this high-risk group of heightened concern 48 . Genetic basis of disease UV radiation plays a critical role in the pathogenesis of BCC, accounting for the high rate of somatic mutations and “UV signatures” seen in this type of carcinoma 49 , 50 . In addition to these “UV signature” genetic alterations, mutations in the patched 1 ( PTCH1 ) gene on chromosome 9q22 have been shown to play a key role in the pathogenesis of sporadic BCC 51 , 52 . Loss of heterozygosity of PTCH1 is the most frequent genetic alteration in BCC, occurring in a reported 53% to 69% of BCCs 53 – 57 . PTCH allele alterations are seen in approximately 83% of BCCs 55 . Critical to this discovery was the characterization of a subset of patients with nevoid BCC syndrome (Gorlin syndrome). This syndrome, first characterized by Gorlin 58 , is an autosomal dominant disorder caused by mutations in the PTCH1 gene, resulting in the inappropriate activation of hedgehog (HH) signaling and an increased risk of BCC and developmental defects 58 – 61 . PTCH1 encodes a protein that functions as the receptor for sonic HH ligands which, when mutated, leads to uncontrolled cell growth and BCC tumorigenesis 60 , 62 . The HH signaling pathway has been the genetic basis for the development of targeted therapies for BCC, which will be discussed below. Though less critical than PTCH1 in the pathogenesis of BCC, p53 is another important tumor suppressor gene that has been implicated in BCC tumorigenesis 54 . P53 plays a critical role in DNA repair and cell cycle regulation 63 and has altered expression in a range of tumor types. Reported rates of p53 mutation are between 44% and 56% in BCC 54 , 64 , 65 . Management Targeted molecular therapies Smoothened inhibitors. Several molecular therapies for BCC have focused on the HH signaling pathway. Binding of HH ligands to PTCH1 leads to a loss of inhibition of this pathway, leading to activation of smoothened (SMO), a seven-transmembrane protein downstream of PTCH1 . SMO then interacts with several proteins and ultimately leads to the expression of the GLI family of transcription factors that promote proliferation, survival, and differentiation, key genes involved in BCC tumorigenesis 59 , 66 . Several of the small-molecule targeted therapies therefore have focused on SMO inhibition. Vismodegib. In 2012, vismodegib became the first SMO inhibitor to gain US Food and Drug Administration (FDA) approval. It was approved for use in metastatic BCC (a very rare occurrence), for locally advanced BCC recurrent after surgery, and for patients who are not candidates for surgical resection or radiation. The initial phase 1 trial studied 33 patients with locally advanced BCC treated with vismodegib at one of three doses (150, 270, or 540 mg daily) and found that 18 out of 33 patients responded 67 . Two patients had a complete response, defined as a 100% regression of the visible/palpable lesions, and six had a partial response, defined as a more than 50% reduction in tumor diameter. The median duration of response was 12.8 months 67 . Of the patients who did not respond, 15 had stable disease and four had progression of their BCCs while on treatment 67 . Interestingly, two patients with progressive disease had elevated GLI1 mRNA levels in tissue samples, raising the question of possible resistance mechanisms in these patients. The phase II trial of the efficacy and safety of vismodegib in advanced basal-cell carcinoma (ERIVANCE) by Sekulic et al . led to the approval of vismodegib 68 . This trial enrolled 104 patients (33 patients with metastatic BCC and 71 patients with locally advanced BCC) who took 150 mg daily of vismodegib 68 . In patients with metastatic BCC, the response rate was 30%, whereas in 63 patients with locally advanced BCC, the response rate was 43%. Response rate was defined as a decrease of 30% or more in the externally visible or radiographic dimension or as complete resolution of ulceration (if present at baseline). The median duration of response was 7.6 months 68 and the median progression-free survival was 9.5 months according to independent review. All patients had at least one adverse event, and in 12% of patients, adverse events led to discontinuation of vismodegib. The most common adverse events reported with vismodegib include alopecia, dysgeusia, muscle spasms, weight loss, fatigue, decreased appetite, nausea, and diarrhea 67 – 69 . Similar response rates were seen in a subsequent open-label, two-cohort, multicenter study of 119 patients with advanced BCC who were poor candidates for surgical resection or radiotherapy. They were also treated with vismodegib 150 mg daily. Response rates were 30.8% for those with metastatic disease and 46.4% for those with locally advanced BCC 70 . Of the 115 patients included as efficacy-evaluable patients, about half (49.5%) experienced stable disease—27 out of 56 patients with locally advanced BCC and 20 out of 39 patients with metastatic BCC. The median treatment period was 5.5 months, and the most common adverse events reported were muscle spasms, dysgeusia, alopecia, and diarrhea 70 . The study of vismodegib in patients with advanced basal cell carcinoma (STEVIE) is the largest vismodegib trial to date; 499 patients (468 with locally advanced BCC and 31 with metastatic disease) 71 . Objective responses were seen in 66.7% of patients with locally advanced BCC and 37.9% of those with metastatic disease. The median time to response for both groups was 2.7 months, and the median duration of the response was 22.7 months. The median duration of vismodegib treatment was 36.4 weeks, and 80% of patients discontinued therapy (36% due to adverse events, 14% due to progressive disease, and 10% from patient request to stop treatment). Vismodegib has recently been evaluated as a neoadjuvant to surgery for high-risk BCC 72 . An open-label single-arm study of 15 enrolled patients examined vismodegib 150 mg/day as neoadjuvant for a goal of 3 to 6 months of therapy prior to surgical resection 72 . A total of 11 out of 15 patients completed the trial. Of the four who could not complete the trial, one was lost to follow-up and two withdrew due to vismodegib-related side effects and one due to an unrelated adverse event. Of the 13 BCCs that were selected for surgery, vismodegib reduced the surgical defect area by 27% from baseline. In the non-recurrent tumors (9 out of 13), vismodegib reduced the surgical defect area by 36%; however, for the recurrent BCCs (4 out of 13), there was no reduction in surgical defect area, introducing the possibility that these tumors had acquired mutations that rendered them resistant to the effects of vismodegib. Owing to the genetic basis of nevoid basal cell nevus syndrome, patients with this disorder are of particular interest for treatment with SMO inhibitors. A randomized, double-blind, placebo-controlled trial by Tang et al . examined treatment with vismodegib in 41 patients with nevoid basal cell nevus syndrome 73 . After 3 months of therapy, the number of new surgically eligible BCCs was significantly reduced in the vismodegib-treated group as compared with the placebo group (mean of 2 versus 29, respectively, of new surgically eligible BCCs per year) 73 . Unfortunately, 54% of patients (14 out of 26) receiving vismodegib discontinued treatment because of adverse drug side effects. Overall, while the results of vismodegib treatment have been promising, there remain important questions regarding durability of the response, long-term tolerability of the adverse effects, and acquisition of resistant mutations over time. Sonidegib. Sonidegib is an SMO inhibitor that gained FDA approval in 2015 for treatment of patients with locally advanced BCC who are not candidates for curative surgery or radiation 74 . Approval was based on data from the phase II randomized, double-blind Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial assessing the efficacy of sonidegib for metastatic or locally advanced BCC 75 . A total of 230 patients were enrolled and placed on either 200 or 800 mg daily, and objective response rates were 36% (20 out of 55) and 34% (39 out of 116), respectively. There were both greater response rates and fewer adverse events in the 200mg dose sonidegib group as compared with the 800 mg group 75 . In analyzing objective response rates for tumor types, 43% and 38% of patients with locally advanced BCC and 15% and 17% of patients with metastatic BCC responded in the 200 and 800 mg dosing schedules, respectively. The median time to tumor response was 4 months, and median progression-free survival was 22.1 months 75 – 78 . The adverse effect profile of sonidegib is similar to that of vismodegib. Although there are no direct head-to-head comparisons of vismodegib with sonidegib, objective response rates were similar using BCC modified Response Criteria In Solid Tumors (BCC-mRECIST), at 48% in the ERIVANCE (vismodegib, 150 mg daily) study with a minimum follow-up of 21 months, and 56% in the BOLT (sonidegib, 200 mg daily) trial with a minimum follow-up of 18 months 68 , 69 , 78 . It should be noted that this is an indirect comparison that should be interpreted with caution. Further randomized, double-blind controlled trials comparing both the safety and efficacy of both SMO inhibitors are needed. Hedgehog pathway resistance. Primary and secondary drug resistances to SMO inhibitors have been reported. Novel heterozygous missense SMO mutations were sequenced in recurrent and resistant BCC tissue to vismodegib 79 , 80 . In cases of secondary resistance, the SMO mutations that were isolated were not present in the primary tumors that had originally responded to treatment, and distinct recurrent nodules of BCC demonstrated unique SMO mutations, suggesting a heterogeneous and dynamic mechanism of resistance that can rapidly arise in recurrent tumor tissue 79 . In cases of primary resistance in the tumor tissue of origin, given the cost of treatment with SMO inhibitors as compared with genetic sequencing, it may be more cost-effective for all patients to undergo screening prior to the initiation of targeted therapy. Interestingly, a study of nine patients with advanced BCC resistant to treatment with vismodegib also demonstrated resistance to sonidegib, suggesting that chemoresistance can occur between different SMO inhibitors 81 . It is appropriate to consider cost in deciding therapeutic options. According to Centers for Medicare and Medicaid Services (CMS) data from 1992 to 1995, the cost per episode of care for NMSC was estimated at $492 in the outpatient setting 82 . In a more recent study comparing the economic cost of treating patients with advanced versus non-advanced BCC from 2010 to 2014, the mean cost of treating an advanced BCC was $11,143 compared with $1,171 for a non-advanced BCC 83 . The majority of patients with advanced BCC (93.7%, n = 794) received radiation therapy, at a mean cost of $10,317. Of the 847 patients with advanced BCCs, only three received vismodegib. The cost of vismodegib is $250 per capsule or $7,500 per month 83 . Treatment length varies by patient, and the treatment is not curative per se, but rather suppressive. However, an expected 10-month treatment course of vismodegib costs approximately $75,000 84 . It is important to reserve this treatment approach for patients who are not candidates for surgery or radiation. Mohs, surgical excision, and electrodessication and curettage Standard surgical excision with 4-mm margins is the recommended treatment for BCCs with non-aggressive histology, size of less than 2 cm, and occurrence on low-risk sites where tissue sparing is not critical (trunk and extremities) 85 . With 4-mm surgical margins, 95% of cases of BCC less than 2 cm were cleared with standard excision 86 . BCC of the face demonstrates high rates of incomplete excision, and greater efficacy has been demonstrated using Mohs micrographic surgery (MMS) as compared with standard excision 87 – 92 . Five-year rates of recurrence following MMS for primary BCC are approximately 1.4% to 3.2% for primary and 2.4% to 6.7% for recurrent BCCs 89 – 91 . Low rates of recurrence in MMS are attributed to optimal margin control given full histologic examination at the time of surgery of all peripheral and deep margins. MMS is recommended in cases of aggressive histology, recurrent BCC, and critical areas of skin conservation (head, neck, genitalia, hand/feet, nipples, and so on) and for tumors of large size (more than 2 cm) 85 . Electrodessication and curettage (EDC) has been used for decades to treat BCC. Although this can be a cost-effective treatment, cure rates are highly operator-dependent. One study demonstrated five-year recurrence rates at 5.7% to 18.1% depending on the skill level of the physician 93 . Higher recurrence rates were seen on the forehead, paranasal areas, and nose, and overall cosmesis tends to be poor in the head and neck regions. For these reasons, this treatment is now rarely recommended for BCC in these locations. Topical therapy Imiquimod. Imiquimod 5% is a topical Toll-like receptor 7 agonist approved by the FDA for treatment of superficial BCCs less than 2 cm in diameter. A recent randomized controlled trial comparing imiquimod 5% cream (daily for 6 weeks in superficial BCC and daily for 12 weeks in nodular BCC) with surgical excision found five-year success rates of 82.5% for the imiquimod treatment group and 97.7% for the standard surgical excision group 94 . A randomized, vehicle-controlled study of subjects with superficial BCC treated with imiquimod 5 to 7 times per week for 6 weeks as compared with vehicle showed composite clinical and histologic clearance rates of 75% for imiquimod 5 times per week and 73% for imiquimod 7 times per week 95 . Imiquimod is generally well tolerated, but the most common treatment effects include erythema, crusting, erosions, and scabbing, which correlate positively with histologic clearance rates 96 . A randomized single-blind, non-inferiority randomized controlled trial demonstrated topical treatment with imiquimod 5% (daily, 5 times per week for 6 weeks) to be superior to methylaminolevulinate-photodynamic therapy (MAL-PDT) with the proportion of patients with successful disease clearance at 3 and 12 months to be 72.8% for MAL-PDT as compared with 83.4% for imiquimod 97 . Imiquimod is considered a useful treatment modality for predominantly superficial BCC in patients who are poor candidates for surgical or destructive modalities. 5-Fluorouracil. 5-Fluorouracil (5-FU) is a topical pyrimidine analog which functions as an antimetabolite, interfering with DNA synthesis. 5-FU is FDA-approved for treatment of superficial BCC. A double-blind randomized trial of 13 patients showed a 90% cure rate in lesions treated with 5% 5-FU twice daily for two weeks 98 , and another study of 5% 5-FU twice daily for up to 12 weeks showed a similar histologic cure rate of 90%. The efficacy of Efudex 5% was reported to be comparable to that of MAL-PDT and to have a clearance rate of 80.1% in a single-blind, randomized controlled trial 97 . Erythema, erosions, and ulceration are the most common side effects with use of 5-FU. Photodynamic therapy. PDT uses photosensitizing agents—aminolevulinic acid (ALA) or MAL—to create a photochemical reaction by producing activated oxygen species that destroy cancer cells when exposed to oxygen and light 99 . Photosensitizing agents act through intracellular protoporphyrin IX, which preferentially accumulates in tumor tissues. In a randomized prospective study of excision versus MAL-PDT for nodular BCC at five years, the complete response rates were 76% for MAL-PDT and 96% for excisional surgery, and recurrence rates were 14% with MAL-PDT and 4% for those who underwent excision 100 . A recent randomized controlled trial comparing effectiveness of ALA-PDT with surgical excision found five-year recurrence rates of 30.7% for ALA-PDT and 2.3% for surgical excision 101 . While recurrence rates are higher for PDT-treated BCCs, cosmesis was found to be superior to surgical excision 100 , 102 . For superficial BCC, complete response rates ranged between 73% and 92%, and some studies suggest improved efficacy with repeated PDT cycles 97 , 103 – 105 . Although PDT represents an important treatment modality for those who are not good surgical candidates and have a large burden of superficial disease, surgical interventions should remain the standard of care for invasive disease given high recurrence rates with PDT. Radiation therapy Radiotherapy treatment for BCC can be divided into three main categories: conventional external radiotherapy, superficial x-ray therapy, and brachytherapy. A newer irradiation technique is volumetric modulated arc therapy. This modality allows for complex dose distributions to tumor tissue while minimizing involvement of healthy tissue 106 . A detailed examination of these modalities is beyond the scope of this review, but radiation is a valuable treatment for non-surgical candidates and patients who decline invasive treatments. Major disadvantages of radiation include multiple visits, lack of confirmation of histologic clearance, development of aggressive phenotypes in some recurrent tumors, poor long-term cosmesis with conventional radiotherapy, and high cost as compared with surgical treatments 107 . In a randomized trial comparing surgical excision with 2-mm margins versus radiation with brachytherapy, superficial x-ray therapy or conventional radiotherapy showed four-year recurrence rates of 0.7% in patients who underwent surgery versus 7.5% in those who underwent radiotherapy 108 . Rates of BCC recurrence following superficial x-ray have been reported to be 2% at two years and 4.2% at five years 109 . Brachytherapy used as treatment for NMSC has been reported to have good cosmesis and recurrence rates of less than 1% to 1.3% after median follow-up times between 4 and 16.1 months 110 . It is likely that the follow-up interval is not sufficient to determine the true recurrence rates with this modality as compared with more established forms of treatment. External electron beam therapy has shown efficacy rates of 92% at five years in the treatment of NMSC 111 . Chemoprevention Nicotinamide. Nicotinamide, otherwise known as vitamin B 3 , has emerged as an oral therapy with potential for skin cancer prevention. In one study, nicotinamide was found to reduce UV-induced immunosuppression 112 . A recent randomized double-blind controlled trial reported a reduction of 20% in new BCCs at 12 months in patients on treatment with 500 mg nicotinamide twice daily 113 . There are no significant adverse events associated with nicotinamide. While studies have demonstrated a decreased risk of developing NMSC, further investigation is needed to determine the long-term benefits of this treatment 114 . Chemotherapy and immune checkpoint inhibitors Targeted SMO inhibitors have largely replaced other forms of chemotherapy for advanced or metastatic BCC. Cituximab showed efficacy in certain cases of metastatic BCC or nevoid BCC syndrome 115 , 116 . Newer immunotherapies have emerged that target programmed death 1 (PD-1) immune checkpoint receptors and ligands. A recent case report of a patient with metastatic BCC who failed therapy with vismodegib showed a partial response to an anti–PD-1 monoclonal antibody 117 . In another recent case report, a 58-year-old male with metastatic BCC who failed therapy with vismodegib, paclitaxel, and cisplatin was placed on the anti–PD-1 antibody, nivolumab, at 240 mg intravenously every 2 weeks. The patient demonstrated near complete resolution of metastatic disease within 4 months of treatment 118 . Conclusions MMS and surgical excision remain the standard of care for treating BCC. However, new targeted molecular therapies now provide effective treatment options for patients with locally advanced or metastatic BCC. Topical therapies may be effective in treating superficial disease in many cases, although careful surveillance is needed to confirm tumor clearance. Further randomized prospective studies are needed to examine the long-term effectiveness of these alternative modalities and their ability to decrease overall morbidity. Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. F1000 recommended References 1. Stern RS: Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol. 2010; 146 (3): 279–82. PubMed Abstract | Publisher Full Text 2. Rogers HW, Weinstock MA, Harris AR, et al. : Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146 (3): 283–7. PubMed Abstract | Publisher Full Text | F1000 Recommendation 3. Lomas A, Leonardi-Bee J, Bath-Hextall F: A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166 (5): 1069–80. PubMed Abstract | Publisher Full Text 4. Bath-Hextall F, Leonardi-Bee J, Smith C, et al. : Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer. 2007; 121 (9): 2105–8. PubMed Abstract | Publisher Full Text 5. Birch-Johansen F, Jensen A, Mortensen L, et al. : Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish women. Int J Cancer. 2010; 127 (9): 2190–8. PubMed Abstract | Publisher Full Text 6. Christenson LJ, Borrowman TA, Vachon CM, et al. : Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005; 294 (6): 681–90. PubMed Abstract | Publisher Full Text 7. Miller DL, Weinstock MA: Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994; 30 (5 Pt 1): 774–8. PubMed Abstract | Publisher Full Text 8. Weinstock MA: Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back Study. J Invest Dermatol. 1994; 102 (6): 6S–9. PubMed Abstract 9. Verkouteren JAC, Ramdas KHR, Wakkee M, et al. : Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017; 177 (2): 359–72. PubMed Abstract | Publisher Full Text | F1000 Recommendation 10. Chen JT, Kempton SJ, Rao VK: The Economics of Skin Cancer: An Analysis of Medicare Payment Data. Plast Reconstr Surg Glob Open. 2016; 4 (9): e868. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 11. Guy GP Jr, Holman DM, Watson M: The Important Role of Schools in the Prevention of Skin Cancer. JAMA Dermatol. 2016; 152 (10): 1083–4. PubMed Abstract | Publisher Full Text 12. Bauer A, Diepgen TL, Schmitt J: Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. Br J Dermatol. 2011; 165 (3): 612–25. PubMed Abstract | Publisher Full Text 13. Gailani MR, Leffell DJ, Ziegler A, et al. : Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst. 1996; 88 (6): 349–54. PubMed Abstract | Publisher Full Text 14. Situm M, Buljan M, Bulat V, et al. : The role of UV radiation in the development of basal cell carcinoma. Coll Antropol. 2008; 32 Suppl 2 : 167–70. PubMed Abstract 15. Narayanan DL, Saladi RN, Fox JL: Ultraviolet radiation and skin cancer. Int J Dermatol. 2010; 49 (9): 978–86. PubMed Abstract | Publisher Full Text 16. Gallagher RP, Hill GB, Bajdik CD, et al. : Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995; 131 (2): 157–63. PubMed Abstract | Publisher Full Text 17. Iannacone MR, Wang W, Stockwell HG, et al. : Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study. BMC Cancer. 2012; 12 : 417. PubMed Abstract | Publisher Full Text | Free Full Text 18. Rosso S, Zanetti R, Martinez C, et al. : The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer. 1996; 73 (11): 1447–54. PubMed Abstract | Publisher Full Text | Free Full Text 19. Kricker A, Armstrong BK, English DR, et al. : Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer. 1995; 60 (4): 489–94. PubMed Abstract | Publisher Full Text 20. Colantonio S, Bracken MB, Beecker J: The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol. 2014; 70 (5): 847–57.e1-18. PubMed Abstract | Publisher Full Text 21. Cust AE, Armstrong BK, Goumas C, et al. : Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer. 2011; 128 (10): 2425–35. PubMed Abstract | Publisher Full Text | Free Full Text 22. Ferrucci LM, Cartmel B, Molinaro AM, et al. : Indoor tanning and risk of early-onset basal cell carcinoma. J Am Acad Dermatol. 2012; 67 (4): 552–62. PubMed Abstract | Publisher Full Text | Free Full Text 23. Lazovich D, Vogel RI, Berwick M, et al. : Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev. 2010; 19 (6): 1557–68. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 24. Wehner MR, Shive ML, Chren M, et al. : Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ. 2012; 345 : e5909. PubMed Abstract | Publisher Full Text | Free Full Text 25. Box NF, Duffy DL, Irving RE, et al. : Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol. 2001; 116 (2): 224–9. PubMed Abstract | Publisher Full Text 26. Cust AE, Goumas C, Vuong K, et al. : MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study. BMC Cancer. 2013; 13 : 406. PubMed Abstract | Publisher Full Text | Free Full Text 27. Dwyer T, Stankovich JM, Blizzard L, et al. : Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? Am J Epidemiol. 2004; 159 (9): 826–33. PubMed Abstract | Publisher Full Text 28. Molinaro AM, Ferrucci LM, Cartmel B, et al. : Indoor tanning and the MC1R genotype: risk prediction for basal cell carcinoma risk in young people. Am J Epidemiol. 2015; 181 (11): 908–16. PubMed Abstract | Publisher Full Text | Free Full Text 29. Scherer D, Bermejo JL, Rudnai P, et al. : MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer. 2008; 122 (8): 1787–93. PubMed Abstract | Publisher Full Text 30. Smith AG, Box NF, Marks LH, et al. : The human melanocortin-1 receptor locus: analysis of transcription unit, locus polymorphism and haplotype evolution. Gene. 2001; 281 (1–2): 81–94. PubMed Abstract | Publisher Full Text 31. Asgari MM, Moffet HH, Ray GT, et al. : Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998–2012. JAMA Dermatol. 2015; 151 (9): 976–81. PubMed Abstract | Publisher Full Text | F1000 Recommendation 32. Flohil SC, Seubring I, van Rossum MM, et al. : Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol. 2013; 133 (4): 913–8. PubMed Abstract | Publisher Full Text 33. Moriwaki S, Ray S, Tarone RE, et al. : The effect of donor age on the processing of UV-damaged DNA by cultured human cells: reduced DNA repair capacity and increased DNA mutability. Mutat Res. 1996; 364 (2): 117–23. PubMed Abstract | Publisher Full Text 34. Wei Q, Matanoski GM, Farmer ER, et al. : DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci U S A. 1993; 90 (4): 1614–8. PubMed Abstract | Publisher Full Text | Free Full Text 35. Naldi L, DiLandro A, D'Avanzo B, et al. : Host-related and environmental risk factors for cutaneous basal cell carcinoma: evidence from an Italian case-control study. J Am Acad Dermatol. 2000; 42 (3): 446–52. PubMed Abstract | Publisher Full Text 36. van Dam RM, Huang Z, Rimm EB, et al. : Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol. 1999; 150 (5): 459–68. PubMed Abstract | Publisher Full Text 37. Zhang Y, Cartmel B, Choy CC, et al. : Body mass index, height and early-onset basal cell carcinoma in a case-control study. Cancer Epidemiol. 2017; 46 : 66–72. PubMed Abstract | Publisher Full Text | Free Full Text 38. Wollina U, Tchernev G: Advanced basal cell carcinoma. Wien Med Wochenschr. 2013; 163 (15–16): 347–53. PubMed Abstract | Publisher Full Text 39. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. : Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation. 2010; 89 (10): 1231–8. PubMed Abstract | Publisher Full Text 40. Forchetti G, Suppa M, Del Marmol V: Overview on non-melanoma skin cancers in solid organ transplant recipients. G Ital Dermatol Venereol. 2014; 149 (4): 383–7. PubMed Abstract 41. Tessari G, Girolomoni G: Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg. 2012; 38 (10): 1622–30. PubMed Abstract | Publisher Full Text 42. Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med. 2003; 348 (17): 1681–91. PubMed Abstract | Publisher Full Text 43. Moloney FJ, Comber H, O'Lorcain P, et al. : A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006; 154 (3): 498–504. PubMed Abstract | Publisher Full Text 44. Berg D, Otley CC: Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002; 47 (1): 1–17; quiz 18–20. PubMed Abstract | Publisher Full Text 45. Kalinova L, Majek O, Stehlik D, et al. : Skin cancer incidence in renal transplant recipients - a single center study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010; 154 (3): 257–60. PubMed Abstract 46. Zwald FO, Brown M: Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011; 65 (2): 253–61; quiz 262. PubMed Abstract | Publisher Full Text 47. Hartevelt MM, Bavinck JN, Kootte AM, et al. : Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990; 49 (3): 506–9. PubMed Abstract | Publisher Full Text 48. Garrett GL, Blanc PD, Boscardin J, et al. : Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA Dermatol. 2017; 153 (3): 296–303. PubMed Abstract | Publisher Full Text | F1000 Recommendation 49. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. : Signatures of mutational processes in human cancer. Nature. 2013; 500 (7463): 415–21. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 50. Jayaraman SS, Rayhan DJ, Hazany S, et al. : Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol. 2014; 134 (1): 213–20. PubMed Abstract | Publisher Full Text 51. Gailani MR, Bale AE: Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst. 1997; 89 (15): 1103–9. PubMed Abstract | Publisher Full Text 52. Gailani MR, Bale SJ, Leffell DJ, et al. : Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992; 69 (1): 111–7. PubMed Abstract | Publisher Full Text 53. Quinn AG, Campbell C, Healy E, et al. : Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. J Invest Dermatol. 1994; 102 (3): 300–3. PubMed Abstract 54. van der Riet P, Karp D, Farmer E, et al. : Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. Cancer Res. 1994; 54 (1): 25–7. PubMed Abstract 55. Reifenberger J, Wolter M, Knobbe CB, et al. : Somatic mutations in the PTCH , SMOH , SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005; 152 (1): 43–51. PubMed Abstract | Publisher Full Text 56. Kim MY, Park HJ, Baek SC, et al. : Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci. 2002; 29 (1): 1–9. PubMed Abstract | Publisher Full Text 57. Ling G, Ahmadian A, Persson A, et al. : PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001; 20 (53): 7770–8. PubMed Abstract | Publisher Full Text 58. Gorlin RJ: Nevoid basal cell carcinoma syndrome. Dermatol Clin. 1995; 13 (1): 113–25. PubMed Abstract 59. Epstein EH: Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008; 8 (10): 743–54. PubMed Abstract | Publisher Full Text | Free Full Text 60. Johnson RL, Rothman AL, Xie J, et al. : Human homolog of patched , a candidate gene for the basal cell nevus syndrome. Science. 1996; 272 (5268): 1668–71. PubMed Abstract | Publisher Full Text 61. Aszterbaum M, Rothman A, Johnson RL, et al. : Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998; 110 (6): 885–8. PubMed Abstract | Publisher Full Text 62. Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, et al. : The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996; 14 (1): 78–81. PubMed Abstract | Publisher Full Text 63. Bieging KT, Mello SS, Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014; 14 (5): 359–70. PubMed Abstract | Publisher Full Text | Free Full Text 64. Rady P, Scinicariello F, Wagner RF Jr, et al. : p53 mutations in basal cell carcinomas. Cancer Res. 1992; 52 (13): 3804–6. PubMed Abstract 65. Ziegler A, Leffell DJ, Kunala S, et al. : Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A. 1993; 90 (9): 4216–20. PubMed Abstract | Publisher Full Text | Free Full Text 66. Kudchadkar R, Lewis K, Gonzalez R: Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors. Semin Oncol. 2012; 39 (2): 139–44. PubMed Abstract | Publisher Full Text 67. Von Hoff DD, LoRusso PM, Rudin CM, et al. : Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361 (12): 1164–72. PubMed Abstract | Publisher Full Text | F1000 Recommendation 68. Sekulic A, Migden MR, Oro AE, et al. : Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366 (23): 2171–9. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 69. Rudnick EW, Thareja S, Cherpelis B: Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. Int J Dermatol. 2016; 55 (3): 249–58; quiz 256, 258. PubMed Abstract | Publisher Full Text 70. Chang AL, Solomon JA, Hainsworth JD, et al. : Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014; 70 (1): 60–9. PubMed Abstract | Publisher Full Text 71. Basset-Seguin N, Hauschild A, Grob JJ, et al. : Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16 (6): 729–36. PubMed Abstract | Publisher Full Text | F1000 Recommendation 72. Ally MS, Aasi S, Wysong A, et al. : An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014; 71 (5): 904–911.e1. PubMed Abstract | Publisher Full Text 73. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. : Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366 (23): 2180–8. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 74. Casey D, Demko S, Shord S, et al. : FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clin Cancer Res. 2017; 23 (10): 2377–81. PubMed Abstract | Publisher Full Text 75. Migden MR, Guminski A, Gutzmer R, et al. : Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015; 16 (6): 716–28. PubMed Abstract | Publisher Full Text | F1000 Recommendation 76. Chen L, Silapunt S, Migden MR: Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016; 12 (18): 2095–105. PubMed Abstract | Publisher Full Text 77. Dummer R, Guminski A, Gutzmer R, et al. : The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016; 75 (1): 113–125.e5. PubMed Abstract | Publisher Full Text 78. Lear J, GA, Gutzmer R: A phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with advanced basalcell carcinoma: the BOLT 18-month analysis [abstract]. In: 24th EADV Congress . 2015. 79. Brinkhuizen T, Reinders MG, van Geel M, et al. : Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014; 71 (5): 1005–8. PubMed Abstract | Publisher Full Text 80. Pricl S, Cortelazzi B, Dal Col V, et al. : Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015; 9 (2): 389–97. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 81. Danial C, Sarin KY, Oro AE, et al. : An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res. 2016; 22 (6): 1325–9. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 82. Chen JG, Fleischer AB Jr, Smith ED, et al. : Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001; 27 (12): 1035–8. PubMed Abstract | Publisher Full Text 83. Migden M, Xie J, Wei J, et al. : Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol. 2017; 77 (1): 55–62.e3. PubMed Abstract | Publisher Full Text | F1000 Recommendation 84. Haves AW, Schaffer PR, Carucci JA: The impact of inoperable advanced basal cell carcinoma: the economic, physical, and psychological burden of the disease. J Drugs Dermatol. 2013; 12 (10 Suppl): s151–3. PubMed Abstract 85. American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, et al. : AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. Dermatol Surg. 2012; 38 (10): 1582–603. PubMed Abstract | Publisher Full Text | F1000 Recommendation 86. Wolf DJ, Zitelli JA: Surgical margins for basal cell carcinoma. Arch Dermatol. 1987; 123 (3): 340–4. PubMed Abstract | Publisher Full Text 87. Kimyai-Asadi A, Alam M, Goldberg LH, et al. : Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol. 2005; 53 (3): 464–8. PubMed Abstract | Publisher Full Text | F1000 Recommendation 88. Farhi D, Dupin N, Palangié A, et al. : Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg. 2007; 33 (10): 1207–14. PubMed Abstract | F1000 Recommendation 89. Leibovitch I, Huilgol SC, Selva D, et al. : Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005; 53 (3): 452–7. PubMed Abstract | Publisher Full Text | F1000 Recommendation 90. Mosterd K, Krekels GA, Nieman FH, et al. : Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol. 2008; 9 (12): 1149–56. PubMed Abstract | Publisher Full Text | F1000 Recommendation 91. Smeets NW, Kuijpers DI, Nelemans P, et al. : Mohs' micrographic surgery for treatment of basal cell carcinoma of the face--results of a retrospective study and review of the literature. Br J Dermatol. 2004; 151 (1): 141–7. PubMed Abstract | Publisher Full Text 92. Bozan A, Gode S, Kaya I, et al. : Long-term Follow-up of Positive Surgical Margins in Basal Cell Carcinoma of the Face. Dermatol Surg. 2015; 41 (7): 761–7. PubMed Abstract | Publisher Full Text | F1000 Recommendation 93. Kopf AW, Bart RS, Schrager D, et al. : Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol. 1977; 113 (4): 439–43. PubMed Abstract | Publisher Full Text 94. Williams HC, Bath-Hextall F, Ozolins M, et al. : Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. J Invest Dermatol. 2017; 137 (3): 614–9. PubMed Abstract | Publisher Full Text | F1000 Recommendation 95. Geisse J, Caro I, Lindholm J, et al. : Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004; 50 (5): 722–33. PubMed Abstract | Publisher Full Text | F1000 Recommendation 96. Geisse JK, Rich P, Pandya A, et al. : Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002; 47 (3): 390–8. PubMed Abstract | Publisher Full Text | F1000 Recommendation 97. Arits H, Mosterd K, Essers BA, et al. : Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013; 14 (7): 647–54. PubMed Abstract | Publisher Full Text | F1000 Recommendation 98. Romagosa R, Saap L, Givens M, et al. : A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg. 2000; 26 (4): 338–40. PubMed Abstract | Publisher Full Text 99. Zeitouni NC, Oseroff AR, Shieh S: Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol. 2003; 39 (17–18): 1133–6. PubMed Abstract | Publisher Full Text 100. Rhodes LE, de Rie MA, Leifsdottir R, et al. : Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007; 143 (9): 1131–6. PubMed Abstract | Publisher Full Text | F1000 Recommendation 101. Roozeboom MH, Aardoom MA, Nelemans PJ, et al. : Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol. 2013; 69 (2): 280–7. PubMed Abstract | Publisher Full Text | F1000 Recommendation 102. Bath-Hextall FJ, Perkins W, Bong J, et al. : Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007; (1): CD003412. PubMed Abstract | Publisher Full Text | F1000 Recommendation 103. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. : Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008; 18 (5): 547–53. PubMed Abstract 104. Roozeboom MH, Arits AH, Nelemans PJ, et al. : Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012; 167 (4): 733–56. PubMed Abstract | Publisher Full Text | F1000 Recommendation 105. Szeimies RM, Ibbotson S, Murrell DF, et al. : A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008; 22 (11): 1302–11. PubMed Abstract | Publisher Full Text | F1000 Recommendation 106. Wollina U, Schreiber A, Merla K, et al. : Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Reports. 2011; 3 (3): e57. PubMed Abstract | Publisher Full Text | Free Full Text 107. Smith V, Walton S: Treatment of facial Basal cell carcinoma: a review. J Skin Cancer. 2011; 2011 : 380371. PubMed Abstract | Publisher Full Text | Free Full Text 108. Avril MF, Auperin A, Margulis A, et al. : Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997; 76 (1): 100–6. PubMed Abstract | Publisher Full Text | Free Full Text 109. Cognetta AB, Howard BM, Heaton HP, et al. : Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012; 67 (6): 1235–41. PubMed Abstract | Publisher Full Text 110. Paravati AJ, Hawkins PG, Martin AN, et al. : Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol. 2015; 5 (6): e659–64. PubMed Abstract | Publisher Full Text | F1000 Recommendation 111. Locke J, Karimpour S, Young G, et al. : Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001; 51 (3): 748–55. PubMed Abstract | Publisher Full Text 112. Yiasemides E, Sivapirabu G, Halliday GM, et al. : Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis. 2009; 30 (1): 101–5. PubMed Abstract | Publisher Full Text 113. Chen AC, Martin AJ, Choy B, et al. : A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015; 373 (17): 1618–26. PubMed Abstract | Publisher Full Text | F1000 Recommendation 114. Park SM, Li T, Wu S, et al. : Niacin intake and risk of skin cancer in US women and men. Int J Cancer. 2017; 140 (9): 2023–31. PubMed Abstract | Publisher Full Text | F1000 Recommendation 115. Kalapurakal SJ, Malone J, Robbins KT, et al. : Cetuximab in refractory skin cancer treatment. J Cancer. 2012; 3 : 257–61. PubMed Abstract | Publisher Full Text | Free Full Text 116. Wollina U: Update of cetuximab for non-melanoma skin cancer. Expert Opin Biol Ther. 2014; 14 (2): 271–6. PubMed Abstract | Publisher Full Text 117. Falchook GS, Leidner R, Stankevich E, et al. : Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016; 4 : 70. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 118. Ikeda S, Goodman AM, Cohen PR, et al. : Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1 : pii: 16037. PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 04 Dec 2017 ADD YOUR COMMENT Comment Author details Author details 1 Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA 2 Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery, Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (1) version 1 Published: 04 Dec 2017, 6:2085 https://doi.org/10.12688/f1000research.11314.1 Copyright © 2017 Totonchy M and Leffell D. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Totonchy M and Leffell D. Emerging concepts and recent advances in basal cell carcinoma [version 1; peer review: 2 approved] . F1000Research 2017, 6 (F1000 Faculty Rev):2085 ( https://doi.org/10.12688/f1000research.11314.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Editorial Note on the Review Process Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions . The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. Reviewers who approved this article Desiree Ratner , Department of Dermatology, Mount Sinai Beth Israel Cancer Center West, USA Competing interests: No competing interests were declared. (for version 1) Uwe Wollina , Department of Dermatology & Allergology, Academic Teaching Hospital of the Technical University of Dresden, Germany Competing interests: No competing interests were declared. (for version 1) Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 04 Dec 2017 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 Version 1 04 Dec 17 Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions . The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. Desiree Ratner , Department of Dermatology, Mount Sinai Beth Israel Cancer Center West, USA Competing interests: No competing interests were declared. View more View less Uwe Wollina , Department of Dermatology & Allergology, Academic Teaching Hospital of the Technical University of Dresden, Germany Competing interests: No competing interests were declared. View more View less Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Emerging concepts and recent advances in...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-2085/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-2085/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-2085/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Totonchy M and Leffell D'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-2085/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/6-2085", templates : { twitter : "Emerging concepts and recent advances in basal cell carcinoma. Totonchy M and Leffell D, published by " + "@F1000Research" + ", https://f1000research.com/articles/6-2085/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/11314/12209") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12209"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "28457": 0, "28458": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "8fa2d90a-4d7e-4c67-bd2d-906a0a929301"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });